Johnston Erwin, TRexBio CEO

Ex­clu­sive: Eli Lil­ly boosts in­flam­ma­to­ry dis­ease pipeline, li­cens­es three can­di­dates from TRexBio

Eli Lil­ly is adding three new pre­clin­i­cal can­di­dates to its im­mune and in­flam­ma­to­ry med­i­cines ar­mory through TRexBio, a Bay Area biotech that spe­cial­izes in T reg­u­la­to­ry cells, or Tregs.

In ex­change for glob­al li­cens­es on the can­di­dates — TRB-051, TRB-031, and TRB-041 — TRexBio will get $55 mil­lion up­front. All in all, TRexBio could get over $1.1 bil­lion when fac­tor­ing in down­stream mile­stones. Ac­cord­ing to TRexBio’s web­site, TRB-051 is the fur­thest along, in the IND-en­abling phase.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.